Published in Leukemia on August 28, 2008
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood (2011) 1.75
Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone. Leuk Lymphoma (2010) 1.49
Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol (2012) 1.38
Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia (2009) 1.30
Therapeutic advancement of chronic lymphocytic leukemia. J Hematol Oncol (2012) 0.98
New insights into biology, prognostic factors, and current therapeutic strategies in chronic lymphocytic leukemia. ISRN Oncol (2013) 0.96
Chronic lymphocytic leukemia: treatment options for patients with refractory disease. Cancer (2009) 0.93
Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia. Leuk Lymphoma (2010) 0.92
Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach. Leuk Lymphoma (2011) 0.90
New strategies in chronic lymphocytic leukemia: shifting treatment paradigms. Clin Cancer Res (2014) 0.87
Management of chronic lymphocytic leukemia. Haematologica (2014) 0.85
Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study. Bone Marrow Transplant (2016) 0.84
VDAC1-based peptides: novel pro-apoptotic agents and potential therapeutics for B-cell chronic lymphocytic leukemia. Cell Death Dis (2013) 0.84
Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak. Cell Death Dis (2012) 0.83
Practical approach to management of chronic lymphocytic leukemia. Arch Med Sci (2015) 0.80
The spectrum of use of rituximab in chronic lymphocytic leukemia. Onco Targets Ther (2010) 0.80
Chronic lymphocytic leukemia associated with immunotactoid glomerulopathy: a case report of successful treatment with high-dose methylprednisolone in combination with rituximab followed by alemtuzumab. Leuk Lymphoma (2012) 0.80
A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica (2013) 0.76
Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia. Blood Cancer J (2014) 0.76
Current concepts in diagnosis and treatment of chronic lymphocytic leukemia. Contemp Oncol (Pozn) (2015) 0.75
Chronic lymphocytic leukemia: inception to cure: are we there? Indian J Hematol Blood Transfus (2012) 0.75
Methylprednisolone suppresses the Wnt signaling pathway in chronic lymphocytic leukemia cell line MEC-1 regulated by LEF-1 expression. Int J Clin Exp Pathol (2015) 0.75
Chronic lymphocytic leukaemia. Nat Rev Dis Prim (2017) 0.75
Novel targeted treatment strategies for refractory chronic lymphocytic leukaemia. Ther Adv Hematol (2011) 0.75
Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia. Arch Med Sci (2015) 0.75
Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL). J Blood Med (2010) 0.75
Role of allogeneic transplantation in patients with chronic lymphocytic leukemia in the era of novel therapies: a review. Ther Adv Hematol (2014) 0.75
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer (1977) 53.23
Optimal two-stage designs for phase II clinical trials. Control Clin Trials (1989) 21.03
Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med (2000) 16.30
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood (1996) 13.35
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med (2004) 7.04
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood (2002) 4.65
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol (2005) 4.06
Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol (2001) 3.38
Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol (2001) 2.95
Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol (2001) 1.96
Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. Blood (2002) 1.68
Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol (2002) 1.58
Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood (2001) 1.55
Immune defects in patients with chronic lymphocytic leukemia. Cancer Immunol Immunother (2005) 1.46
Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol (2002) 1.42
Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood (1989) 1.29
High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol (2003) 1.22
High dose methyl prednisolone in refractory chronic lymphocytic leukaemia. Leuk Lymphoma (1999) 0.90
Monoclonal antibody therapy of chronic lymphocytic leukemia. Cancer Immunol Immunother (2005) 0.89
Survival of young patients with chronic lymphocytic leukemia failing fludarabine therapy: a basis for the use of myeloablative therapies. Leuk Lymphoma (1995) 0.88
Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. Br J Haematol (2001) 0.87
Novel therapeutic strategies with alemtuzumab for chronic lymphocytic leukemia. Semin Oncol (2006) 0.80
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med (2001) 4.83
Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood (2000) 4.18
Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest (1998) 3.96
Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood (1999) 3.10
Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med (1993) 3.04
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia (2007) 2.96
Shared idiotypic determinants on antibodies and T-cell-derived suppressor factor specific for the random terpolymer L-glutamic acid60-L-alanine30-L-tyrosine10. J Exp Med (1979) 2.51
Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Res (2001) 2.41
CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood (2000) 2.38
Immunoglobulin VH3 gene products: natural ligands for HIV gp120. Science (1993) 2.08
Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia. J Exp Med (1990) 2.05
Cloning and characterization of CLLD6, CLLD7, and CLLD8, novel candidate genes for leukemogenesis at chromosome 13q14, a region commonly deleted in B-cell chronic lymphocytic leukemia. Cancer Res (2001) 1.93
Idiotypic analysis of anti-GAT antibodies. I. Presence of common idiotypic specificities in both responder and nonresponder mice. J Immunol (1978) 1.79
Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies. J Exp Med (1985) 1.77
Rheumatoid factor and immune networks. Annu Rev Immunol (1987) 1.70
Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. J Immunol (1997) 1.61
TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. J Immunol (2000) 1.60
DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. Cancer Res (1998) 1.53
Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis. Arthritis Rheum (1997) 1.52
Elevated expression of CD80 (B7/BB1) and other accessory molecules on synovial fluid mononuclear cell subsets in rheumatoid arthritis. Arthritis Rheum (1994) 1.52
Functional properties of a unique subset of cytotoxic CD3+ T lymphocytes that express Fc receptors for IgG (CD16/Leu-11 antigen). J Exp Med (1985) 1.51
Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res (1989) 1.45
Genetic influence on the levels of circulating CD5 B lymphocytes. J Immunol (1987) 1.39
Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest (1998) 1.36
Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine. Proc Natl Acad Sci U S A (1992) 1.35
Isolation and characterization of human VkIII germ-line genes. Implications for the molecular basis of human VkIII light chain diversity. J Immunol (1987) 1.35
High-frequency expression of a conserved kappa light-chain variable-region gene in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (1987) 1.35
Expression of the immunoglobulin VH gene 51p1 is proportional to its germline gene copy number. J Clin Invest (1996) 1.35
The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest (1999) 1.33
Characterization of T cell lines and clones from SJL/J and (BALB/c x SJL/J)F1 mice specific for myelin basic protein. J Immunol (1985) 1.31
Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia (2009) 1.30
Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism. J Clin Invest (2001) 1.30
Isolation and characterization of a light chain variable region gene for human rheumatoid factors. J Exp Med (1987) 1.29
Lack of allelic exclusion in B cell chronic lymphocytic leukemia. J Exp Med (1997) 1.28
Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells. J Exp Med (1994) 1.28
Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood (1995) 1.27
Evidence for somatic selection of natural autoantibodies. J Exp Med (1992) 1.26
Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nat Med (1997) 1.26
Normal B cells express 51p1-encoded Ig heavy chains that are distinct from those expressed by chronic lymphocytic leukemia B cells. J Immunol (2001) 1.25
Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation. Leukemia (2005) 1.16
HLA-DQ beta-chain polymorphism linked to myasthenia gravis. Lancet (1986) 1.16
New roles for rheumatoid factor. J Clin Invest (1991) 1.16
Characterization of two immunoglobulin VH genes that are homologous to human rheumatoid factors. Arthritis Rheum (1989) 1.15
Induction of antibodies to a kappa V region by gene immunization. J Immunol (1993) 1.11
Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia (2005) 1.10
Systemic immunological effects of cytokine genes injected into skeletal muscle. Proc Natl Acad Sci U S A (1993) 1.10
Homologous chromosome recombination generating immunoglobulin allotype and isotype switch variants. EMBO J (1986) 1.08
Ig V region gene expression in small lymphocytic lymphoma with little or no somatic hypermutation. J Immunol (1989) 1.08
Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T lymphocytes. J Immunol (1997) 1.06
Immunostimulatory effects of a plasmid expressing CD40 ligand (CD154) on gene immunization. J Immunol (1997) 1.04
Adenovirus vector infection of chronic lymphocytic leukemia B cells. Blood (1996) 1.02
Soluble CD154 in rheumatoid arthritis: elevated plasma levels in cases with vasculitis. J Rheumatol (2001) 1.02
Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood (1993) 1.01
Tumor necrosis factor-alpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10, and CD40L. Cell Immunol (1995) 1.01
Studies of HIV infection and the development of Epstein-Barr virus-related B cell lymphomas following transfer of human lymphocytes to mice with severe combined immunodeficiency. Curr Top Microbiol Immunol (1989) 1.01
Idiotypic and genetic studies of human rheumatoid factors. Arthritis Rheum (1987) 1.00
Analysis of immunoglobulin VH gene repertoire by an anchored PCR-ELISA. Ann N Y Acad Sci (1995) 0.99
Characterization of four homologous L chain variable region genes that are related to 6B6.6 idiotype positive human rheumatoid factor L chains. J Immunol (1989) 0.98
Common clonal origin of chronic lymphocytic leukemia and high-grade lymphoma of Richter's syndrome. Blood (1993) 0.97
A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154. Leukemia (2010) 0.97
Reduction in mitochondrial membrane potential is an early event in Fas-independent CTL-mediated apoptosis. Cell Immunol (1999) 0.97
Heterogeneity among Epstein-Barr virus-seropositive donors in the generation of immunoblastic B-cell lymphomas in SCID mice receiving human peripheral blood leukocyte grafts. Cancer Res (1992) 0.97
Subclonal evolution involving SF3B1 mutations in chronic lymphocytic leukemia. Leukemia (2013) 0.96
Intraclonal diversity in the VH genes expressed by CD5- chronic lymphocytic leukemia-producing pathologic IgM rheumatoid factor. J Immunol (1990) 0.96
Thymidine-phosphorothioate oligonucleotides induce activation and apoptosis of CLL cells independently of CpG motifs or BCL-2 gene interference. Leukemia (2006) 0.95
Presence of common idiotypes on antibodies induced by glutamic acid-lysine-containing terpolymers in responder and nonresponder mice with the Ig-1b heavy chain allotype. Eur J Immunol (1977) 0.95
An anti-B cell autoantibody from Wiskott-Aldrich syndrome which recognizes i blood group specificity on normal human B cells. Eur J Immunol (1992) 0.94
CD40 activation does not protect chronic lymphocytic leukemia B cells from apoptosis induced by cytotoxic T lymphocytes. Blood (2000) 0.94
Function of B cells expressing a human immunoglobulin M rheumatoid factor autoantibody in transgenic mice. J Exp Med (1993) 0.93
Isolation of heavy chain class switch variants of a monoclonal anti-DC1 hybridoma cell line: effective conversion of noncytotoxic IgG1 antibodies to cytotoxic IgG2 antibodies. Hum Immunol (1983) 0.92
Efficient infection of a human T-cell line and of human primary peripheral blood leukocytes with a pseudotyped retrovirus vector. Proc Natl Acad Sci U S A (1996) 0.92
The generation of monoclonal anti-idiotype antibodies to human B cell-derived leukemias and lymphomas. J Immunol (1985) 0.92
Lack of extensive mutations in the VH5 genes used in common B cell chronic lymphocytic leukemia. J Exp Med (1993) 0.92
Favored use of immunoglobulin V(H)4 Genes in AIDS-associated B-cell lymphoma. Blood (1996) 0.91
Further studies on the epitopes of HLA-B7 defined by murine monoclonal antibodies. Hum Immunol (1986) 0.89
Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma. Leukemia (2006) 0.89
Plasmids encoding granulocyte-macrophage colony-stimulating factor and CD154 enhance the immune response to genetic vaccines. Vaccine (2001) 0.89
Anti-B cell autoantibodies encoded by VH 4-21 genes in human fetal spleen do not require in vivo somatic selection. Eur J Immunol (1994) 0.89
The human immunoglobulin V(H) gene repertoire is genetically controlled and unaltered by chronic autoimmune stimulation. J Clin Invest (1996) 0.89
The CLLU1 expression level is a stable and inherent feature of the chronic lymphocytic leukemia clone. Leukemia (2009) 0.88
Molecular characterization of a supratypic cross-reactive idiotype associated with IgM autoantibodies. J Immunol (1991) 0.88
The V4-34 encoded anti-i autoantibodies recognize a large subset of human and mouse B-cells. Blood Cells Mol Dis (1996) 0.88
Human bone marrow and peripheral blood T lymphocyte depletion: efficacy and effects of both T cells and monocytes on growth of hematopoietic progenitors. Blood (1985) 0.87
Susceptibility to multiple sclerosis associated with an immunoglobulin gamma 3 restriction fragment length polymorphism. J Clin Invest (1987) 0.87
Importance of immunoglobulin isotype in therapy of experimental autoimmune encephalomyelitis with monoclonal anti-CD4 antibody. J Immunol (1987) 0.86
Limitations of in vivo IL-12 supplementation strategies to induce Th1 early life responses to model viral and bacterial vaccine antigens. Virology (2000) 0.86
Epstein-Barr virus-induced human B-cell lymphomas in SCID mice reconstituted with human peripheral blood leukocytes. Cancer Res (1992) 0.86
EBV-associated B-cell lymphomas following transfer of human peripheral blood lymphocytes to mice with severe combined immune deficiency. Curr Top Microbiol Immunol (1990) 0.86
Relative seroprevalence of human herpes viruses in patients with chronic lymphocytic leukaemia. Eur J Clin Invest (2009) 0.85